Programmed cell death protein-1 (PD-1), also called CD279, is coded by the PDCD1 gene
and is constitutively expressed on the surface of immune cells. As a receptor and immune …

Blocking the inhibitory receptor PD-1 on antitumour T lymphocytes is the main rationale
underlying the clinical successes of cancer immunotherapies with checkpoint inhibitor (CI) …

Lipopolysaccharide (LPS) as an important inflammatory mediator activates the
innate/adaptive immune system. The existence of LPS in pancreatic ductal adenocarcinoma …

Posttranslational modifications represent a key step in modulating programmed death-1 (PD-
1) functions, but the underlying mechanisms remain incompletely defined. Here, we report …

Background Colorectal cancer (CRC) is one of the most prevalent and deadly tumors
worldwide. The majority of CRC is resistant to anti-programmed cell death-1 (PD-1)-based …

Many studies have shown a special interaction between LAG3 and PD-1 in T cell inhibition,
while the co-expression and effect of LAG3 and PD-1 on T cells in breast cancer patients are …

Cancer cell–intrinsic programmed cell death protein-1 (PD-1) has emerged as a tumor
regulator in an immunity-independent manner, but its precise role in modulating tumor …

The Hippo signaling pathway is a relatively young tumor-related signaling pathway.
Although it was discovered lately, research on it developed rapidly. The Hippo signaling …

A large number of immune cells are present in the tumour microenvironment (TME), of
which, tumour-associated macrophages (TAMs) are among the most important and highly …

Activation of effector T cells leads to upregulation of PD-1, which can inhibit T cell activity
following engagement with its ligand PD-L1. Post-translational modifications (PTMs) …